ClinicalTrials.gg
CompletedNCT06172907YADUpdated Oct 5, 2026Results posted

A Dyadic Intervention for Young Adult Patients With Cancer and Their Partner Caregivers

An interventional study of Young Adults Coping with Cancer Together Intervention in Cancer, Survivorship and Caregiver Burden, sponsored by Massachusetts General Hospital. Completed at 4 sites in United States. Open to participants aged 25 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 5, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
25 Years to 39 Years
Sex
All
01

Study summary

The purpose of this pilot study is to examine the feasibility and acceptability of a brief psychotherapy intervention to improve psychosocial coping and maintain couple relationships among young adults (aged 25-39) with cancer and their caregiving partners.

Read the detailed description

Young adults (YA) with cancer have unique challenges in coping, and their primary partners may experience burden and low self-efficacy related to caregiving. In this single-arm pilot trial, the investigators shall deliver an eight-session intervention to YAs with cancer and their self-identified partners who provide caregiving. The intervention is founded on principles from cognitive-behavioral therapy and couples-focused interventions, tailored for YA. The aim of the study is to assess the feasibility and acceptability of the intervention, which will inform refinements prior to a larger-scale clinical trial. This study will include 10 YAs and their partner-caregivers (N=20). Participants will complete surveys at baseline and after the intervention, and will be invited to complete optional semi-structured exit interviews.

02

Conditions studied

  • Cancer
  • Survivorship
  • Caregiver Burden
  • Psychological Distress
  • Coping Skills
  • Couples

Keywords

  • Young Adult Cancer
  • Cancer Caregiving
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 20 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.

Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Either: (1) Currently receiving active cancer treatment (n=5) or are within two years of completing active treatment (n=5) at Massachusetts General Cancer Center (MGHCC), located in Boston, Massachusetts, United States, OR (2) are the partner of an individual between the ages of 25-39 who is currently receiving treatment at MGHCC (n=5) or who has completed cancer treatment at MGHCC within the past two years (n=5)
  • Either: (1) Indicates a score ≥4 on the National Comprehensive Cancer Network (NCCN) adapted distress thermometer study screening questions, OR (2) are the partner of a participant indicating a score ≥4 on the NCCN adapted distress thermometer study screening questions
  • English-speaking

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled psychosis, active suicidal ideation, or cognitive impairment
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Other
    Young Adults Coping with Cancer Together Intervention

    Young adults with cancer and their partner-caregivers will attend dyadic virtual psychotherapy sessions lasting 45-60 minutes on a weekly basis for eight weeks.

    Behavioral: Young Adults Coping with Cancer Together Intervention

Interventions

  • BehavioralYoung Adults Coping with Cancer Together Intervention

    This intervention is based on cognitive-behavioral therapy and couples' therapy. It aims to improve cancer and caregiving-related self-efficacy and coping, as well as promote relationship maintenance in context of cancer. The intervention will be delivered by a trained mental health practitioner and include didactics, experiential exercises, and home practice.

    Also known as: YAD Intervention

06

What researchers measure

Primary outcomes

  1. Feasibility of Intervention

    Feasibility will be measured by participant rates of enrollment (≥50% of eligible participants enroll), participant retention (≥70% complete the 14-week post-baseline assessment), and intervention attendance (≥70% of participants attending at least 6 of 8 sessions).

    Time frame: 14 +/- 2 Weeks

  2. Acceptability of Intervention

    Acceptability with be measured by satisfaction with the intervention as rated on the Client Satisfaction Questionnaire. The intervention will be deemed acceptable if ≥75% of participants report average satisfaction that exceeds the CSQ's midpoint.

    Time frame: 14 +/- 2 Weeks

07

Results

Posted Oct 5, 2026
Limitations and caveats
This was a small pilot study with no comparison group to evaluate YAD in comparison to the standard of care or an attention-matched control. The sample size was small, which limited our ability to evaluate clinically meaningful differences in psychosocial outcomes over the study period.

Participant flow

From April 2024 to January 2026, study staff invited young adult patients and their partner cargeivers to participate in the young adult dyadic (YAD) intervention. This study was conducted at the Mass General Brigham Cancer Institute (MGBCI) and three community affiliates. Study staff identified potentially eligible patients through electronic health record review from the participating site's oncology clinics and approached during outpatient appointments or via telephone.

Participant flow — Overall Study
MilestoneYoung Adults Dyadic (YAD) Intervention - Patient ParticipantsYoung Adults Dyadic (YAD) Intervention - Partner Caregiver Participants
Started1010
Completed1010
Not completed00

Outcome measures

PrimaryFeasibility of Intervention

Feasibility will be measured by participant rates of enrollment (≥50% of eligible participants enroll), participant retention (≥70% complete the 14-week post-baseline assessment), and intervention attendance (≥70% of participants attending at least 6 of 8 sessions).

Time frame:
14 +/- 2 Weeks
Reported as:
Count of participants · Participants
Feasibility of Intervention
ParticipantsYoung Adults Dyadic (YAD) Intervention - Patient ParticipantsYoung Adults Dyadic (YAD) Intervention - Partner Caregiver Participants
Enrollment Feasibility1010
Retention Feasibility1010
Attendance Feasibility1010
PrimaryAcceptability of Intervention

Acceptability with be measured by satisfaction with the intervention as rated on the Client Satisfaction Questionnaire. The intervention will be deemed acceptable if ≥75% of participants report average satisfaction that exceeds the CSQ's midpoint.

Time frame:
14 +/- 2 Weeks
Reported as:
Count of participants · Participants
Acceptability of Intervention
ParticipantsYoung Adults Dyadic (YAD) Intervention - Patient ParticipantsYoung Adults Dyadic (YAD) Intervention - Partner Caregiver Participants
Acceptability of Intervention1010

Adverse events

Collected over Adverse event data was collected from enrollment until end of follow-up, up to 16 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Young Adults Dyadic (YAD) Intervention - Patient Participants0/10 (0%)0/10 (0%)0/10 (0%)
Young Adults Dyadic (YAD) Intervention - Partner Caregiver Participants0/10 (0%)0/10 (0%)0/10 (0%)

Baseline characteristics

No participants were excluded from analyses at baseline.

Age, Continuous
Age, Continuous(Years)Young Adults Dyadic (YAD) Intervention - Patient ParticipantsYoung Adults Dyadic (YAD) Intervention - Partner Caregiver ParticipantsTotal
Mean33.64 ± 3.2435.26 ± 5.4634.45 ± 4.45
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Young Adults Dyadic (YAD) Intervention - Patient ParticipantsYoung Adults Dyadic (YAD) Intervention - Partner Caregiver ParticipantsTotal
Gender — Woman628
Gender — Man279
Gender — Non-binary112
Gender — Declined to respond101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Young Adults Dyadic (YAD) Intervention - Patient ParticipantsYoung Adults Dyadic (YAD) Intervention - Partner Caregiver ParticipantsTotal
Race — White or of European Background81018
Race — Asian, Asian American or of Asian background101
Race — Option not listed101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Young Adults Dyadic (YAD) Intervention - Patient ParticipantsYoung Adults Dyadic (YAD) Intervention - Partner Caregiver ParticipantsTotal
Ethnicity — Not Hispanic or Latino/a/x10818
Ethnicity — Declined to respond022
08

Study locations

4 sites
  • Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02114, United States
  • Emerson Hospital/MGH Cancer Center
    Concord, Massachusetts 01742, United States
  • Mass General at North Shore Cancer Center
    Danvers, Massachusetts 01923, United States
  • Mass General at Newton Wellesley Hospital
    Newton, Massachusetts 02462, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: jjacobs@mgh.harvard.edu. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Partners Innovations team

Data sharing details ↗ · www.massgeneralbrigham.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Apr 2026, 24 months.

Results were first posted in Oct 2026, 5 months after primary completion.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 24 months is below that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Jun 2026 → Apr 2026 and completion Dec 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2023
First posted
Dec 15, 2023
StartActual
Apr 19, 2024
Primary completionActual
Apr 19, 2026was Jun 2026
CompletionActual
Apr 19, 2026was Dec 2026
Results first posted
Oct 5, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 5, 2026
Results
Results posted
posted Oct 5, 2026
Primary completion
Jun 2026→Apr 19, 2026 (actual)
Oct 5, 2026
Study completion
Dec 2026→Apr 19, 2026 (actual)
Oct 5, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionFeasibility of Intervention: how it is measured was reworded
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Completed
    Results posted
    Primary completion Jun 2026→Apr 19, 2026 (now actual)
    Study completion Dec 2026→Apr 19, 2026 (now actual)
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionFeasibility of Intervention: how it is measured was reworded
    + 5 other changes: index terms, verification date, contact details, site details and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06172907
Responsible party
Jamie Jacobs (Assistant Professor, Harvard Medical School Department of Psychiatry, Massachusetts General Hospital) — Principal investigator
First posted
Dec 15, 2023
Start date
Apr 19, 2024
Primary completion
Apr 19, 2026
Completion
Apr 19, 2026
Results posted
Oct 5, 2026
Last update
Oct 5, 2026

Study contacts

Jamie M Jacobs, Ph.D.
principal investigator · Massachusetts General Hospital
Giselle K Perez, Ph.D.
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion